Furthermore, METTL3 expression is upregulated in AML patients at diagnosis and during relapse, but downregulated upon achieving complete remission, suggesting a potential role of METTL3 in AML drug resistance.250. This evidence concerns the gene METTL3 and acute myeloid leukemia.